ULTRAGENYX PHARMACEUTICAL INC. Payments to Acquire Equity Method Investments
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Payments to Acquire Equity Method Investments of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-17.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireEquityMethodInvestments · last filed 2023-02-17
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire equity method investments for the quarter ending 2020-12-31 was $26.84M.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire equity method investments for the quarter ending 2020-09-30 was $620.00K.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire equity method investments for the quarter ending 2019-12-31 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire equity method investments for the quarter ending 2019-09-30 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire equity method investments for fiscal 2022 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire equity method investments for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire equity method investments for fiscal 2020 was $37.06M, a 158.47% increase from fiscal 2019.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire equity method investments for fiscal 2019 was $14.34M.
| Period end | Payments to Acquire Equity Method Investments 3 month | Payments to Acquire Equity Method Investments 6 month | Payments to Acquire Equity Method Investments 9 month | Payments to Acquire Equity Method Investments 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-17 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-02-17 | |||
| 2020-12-31 | $26.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $27.46M derived: sum of 2 quarters · filed 2023-02-17 | $37.06M 10-K · filed 2023-02-17 | |
| 2020-09-30 | $620.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $10.22M 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | $9.60M 10-Q · filed 2021-08-03 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $0.00 derived: sum of 2 quarters · filed 2022-02-15 | $14.34M 10-K · filed 2022-02-15 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27 | $14.34M 10-Q · filed 2020-10-27 | ||
| 2019-06-30 | $14.34M 10-Q · filed 2020-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |